BeyondSpring

BeyondSpring BYSI Stock

$0.45   -19.092691%
Add to favorites
Market Cap
$18.76M
LOW - HIGH [24H]
$0.45 - $0.55
VOLUME [24H]
$52.69K
P/E Ratio
0
Earnings per share
-$0.20
ISIN
KYG108301006
Price   Prediction

BeyondSpring Price Chart

Sorry, that's all we've gotfor now...

BeyondSpring (BYSI) stock price today is 0.45 USD on Tech Market Small (-19.09% on the day). Updated .

BeyondSpring BYSI Financial and Trading Overview

BeyondSpring stock price 0.45 USD
Previous Close 0.56 USD
Open 0.53 USD
Bid 0.56 USD x 200
Ask 0.96 USD x 200
Day's Range 0.46 - 0.55 USD
52 Week Range 0.42 - 2.44 USD
Volume 50.34K USD
Avg. Volume 263.25K USD
Market Cap 20.37M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -0.2 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

BYSI Valuation Measures

Enterprise Value 22.68M USD
Trailing P/E N/A
Forward P/E -1.0465957
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 1.3366848
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -2.539

Trading Information

BeyondSpring Stock Price History

Beta (5Y Monthly) N/A
52-Week Change -71.28%
S&P500 52-Week Change 10.51%
52 Week High 2.44 USD
52 Week Low 0.42 USD
50-Day Moving Average 0.65 USD
200-Day Moving Average 1.21 USD

BYSI Share Statistics

Avg. Volume (3 month) 263.25K USD
Avg. Daily Volume (10-Days) 65.39K USD
Shares Outstanding 41.41M
Float 32.91M
Short Ratio 32.19
% Held by Insiders 17.28%
% Held by Institutions 13.08%
Shares Short 2.28M
Short % of Float 6.61%
Short % of Shares Outstanding 5.50%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -22.37%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -8935000 USD
Net Income Avi to Common (ttm) -8752000 USD
Diluted EPS (ttm) -0.2
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 580K USD
Total Cash Per Share (mrq) 0.01 USD
Total Debt (mrq) 79K USD
Total Debt/Equity (mrq) 0.52 USD
Current Ratio (mrq) 0.278
Book Value Per Share (mrq) 0.368

Cash Flow Statement

Operating Cash Flow (ttm) -16152000 USD
Levered Free Cash Flow (ttm) -1858875 USD

Profile of BeyondSpring

Country United States
State NJ
City Florham Park
Address 100 Campus Drive
ZIP 07932
Phone 646 305 6387
Website https://beyondspringpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 44

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Q&A For BeyondSpring Stock

What is a current BYSI stock price?

BeyondSpring BYSI stock price today per share is 0.45 USD.

How to purchase BeyondSpring stock?

You can buy BYSI shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BeyondSpring?

The stock symbol or ticker of BeyondSpring is BYSI.

Which industry does the BeyondSpring company belong to?

The BeyondSpring industry is Biotechnology.

How many shares does BeyondSpring have in circulation?

The max supply of BeyondSpring shares is 41.41M.

What is BeyondSpring Price to Earnings Ratio (PE Ratio)?

BeyondSpring PE Ratio is now.

What was BeyondSpring earnings per share over the trailing 12 months (TTM)?

BeyondSpring EPS is -0.2 USD over the trailing 12 months.

Which sector does the BeyondSpring company belong to?

The BeyondSpring sector is Healthcare.

BeyondSpring BYSI included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.07B USD — 24225.3 USD — 24538.78 USD — — 7.07B USD —
us US Tech Capital Market Composite RCMP US 108.78 USD —
+0.08
— — 108.35 USD — 109.95 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
$2.16T
Total marketcap
$70.5B
Total volume
BTC 57.90%   •   ETH 9.96%
Dominance
Select currency